Interviews

Gene therapies can be life-changing for people, but the high cost plus the burden of treatment remain barriers to access and utilization, explained Kevin Niehoff, PharmD, BCMAS, of IPD Analytics.

The US can learn from what other countries are doing well to implement the best programs to improve patient access to care, especially for those who have the worst outcomes, explained Nadine J. Barrett, PhD, MA, MS, FACCC, of Wake Forest University and the Association of Cancer Care Centers.

Matias Sanchez, MD, assistant professor in the Department of Medicine at the University of Illinois Chicago, discussed recent advancements in multiple myeloma treatment, including the potential of cell therapies and bispecific antibodies.

Sandra Cuellar, PharmD, from the University of Illinois Chicago, highlights the critical role of real-world data in shaping reimbursement models for oncology therapies and emphasizes the growing importance of patient-centered care through shared decision-making, precision medicine, and patient-reported outcomes.

Matias Sanchez, MD, assistant professor in the Department of Medicine, Division of Hematology and Oncology, University of Illinois Chicago, emphasizes the importance of patient education and caregiver involvement in managing complex therapies and advises oncologists to confidently integrate advanced treatments.

Palliative care is quality care, and providers and health systems need to do a better job at ensuring there is equity in palliative care, said Nadine J. Barrett, PhD, MA, MS, FACCC, of Wake Forest University and the Association of Cancer Care Centers.

Divya Gupta, MD, assistant professor at Feinberg School of Medicine at Northwestern University, discussed the potential of using circulating tumor DNA and minimal residual disease (MRD) assays for personalized treatment in non–small cell lung cancer (NSCLC), while emphasizing the unmet need for effective second-line therapies for patients without driver mutations.

Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing bispecifics to the community.

On this episode of Managed Care Cast, we speak with the author of a study published in the November 2024 issue of The American Journal of Managed Care® to explore the link between utilization management and physician burnout.

On November 20, the FDA approved bimekizumab (Bimzelx; UCB Pharma) for use in patients with moderate to severe hidradenitis suppurativa.

In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.

The Wellness Way facility was designed to improve access to comprehensive outpatient care and address social determinants of health for a diverse patient population.

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses the latest advancements in HR+/HER2– breast cancer research, as well as the increasing role of genomic profiling in tailoring treatment plans.

In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat non–small cell lung cancer (NSCLC).

The implementation of a risk evaluation mitigation strategy (REMS) program to monitor patients on mavacamten further supports its real-world use, according to Milind Desai, MD, Cleveland Clinic.

Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.

New discoveries in atherosclerosis pathways have shed light on the active mechanisms in other diseases such as chronic kidney disease (CKD) and HIV, paving the way for furture therapeutics.

The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.

A decision from the American Board of Medical Specialties will be made about a new cardiovascular board by this upcoming February.

The connection between brain, mental, and cardiovascular health needs considerable more attention, argues Maureen Hood, PhD, RN, Uniformed Services University.

Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.

The upcoming Greater Philadelphia Business Coalition on Health (GPBCH) 2024 Mental Health Summit aims to address the growing recognition among employers of the critical role mental health plays in workplace productivity and overall well-being.

Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.

Oncology pharmacists play a vital role in managing complex outpatient therapies by assessing patient suitability, educating patients, and implementing protocols to ensure safe and effective treatment.

Rebekah Walker, PhD, a first-time participant from the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, shares the offerings and opportunities at the 2024 American Heart Association (AHA) meeting that excited her and her team.

At our recent Institute for Value-Based Medicine® event hosted with NYU Langone Health, Brita Roy, MD, MPH, MHS, spoke on improving cancer health outcomes through community-clinical partnerships.

In the final part of our interview, Ticiana Leal, MD, Winship Cancer Institute, looks to the future of perioperative care in the non–small cell lung cancer (NSCLC) arena and the importance of risk stratifying patients.

Over time, biosimilars are gaining traction in the US and becoming preferred products, explained James D. Chambers, PhD, of Tufts Medical Center.